Mural Oncology

NEWS

3D illustration of a T cell killing a cancer cell

Opinion

Ten Years After a Seminal Approval, Immuno-oncology Is Poised for the Next Revolution

While some of the initial excitement around immunotherapies has waned, companies—particularly smaller biotechs—are developing newer iterations that will take cancer care to the next level.

November 4, 2024

·

4 min read

·

IN THE PRESS

Press Releases

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 3, 2024

December 4, 2024

·

2 min read

Press Releases

Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer

November 21, 2024

·

7 min read

Press Releases

Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress

November 13, 2024

·

12 min read

Press Releases

Mural Oncology to Participate in Two Upcoming Investor Conferences

November 11, 2024

·

1 min read

Press Releases

Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

November 8, 2024

·

10 min read

Press Releases

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 4, 2024

·

2 min read

Press Releases

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 2, 2024

October 21, 2024

·

2 min read

Press Releases

Mural Oncology to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

October 8, 2024

·

6 min read

Press Releases

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 2, 2024

October 3, 2024

·

2 min read

Press Releases

Mural Oncology’s First Virtual Investor Day to Highlight Late-Stage Clinical Progress

September 27, 2024

·

11 min read

JOBS